Literature DB >> 11602409

Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes.

S Tauro1, M D Hepburn, D T Bowen, M J Pippard.   

Abstract

BACKGROUND AND OBJECTIVES: The regulation of hematopoiesis by marrow stroma in vitro, has been shown to be abnormal in some patients with myelodysplastic syndromes (MDS). This study was performed to assess whether a range of mechanisms may be altered within the MDS microenvironment. DESIGN AND METHODS: The effects of diffusible factors produced by normal or MDS stromal layers on hematopoietic cells were studied by comparing the ability of media conditioned (CM) by normal or MDS stroma to regulate migration of target normal marrow CD34+ cells across 5 microm transmembranes. The ability of CM to stimulate hematopoietic cells was also assessed: changes in membrane polarity of KG-1a cells on exposure to stroma CM were compared. Subsequently, contact-mediated interactions between normal marrow CD34+ cells and normal and MDS stroma were studied: survival of allogeneic normal marrow CD34+ cells on live and glutaraldehyde-fixed normal and myelodysplastic stroma after 24h of co-culture was measured using 7-aminoactinomycin D staining. To determine whether hematopoietic cell survival on normal and MDS stroma was related to oxidative stress within the stromal microenvironment, intracellular superoxide levels, both constitutively and induced by tumor necrosis factor-a were measured within live stromal cells by FACScan analysis of ethidium bromide stained cells.
RESULTS: The ability of CM from normal and MDS stroma to regulate short-term migration and activation of hematopoietic cells was similar. The mean percentage of apoptotic CD34+ cells (13+/-11%) adherent to glutaraldehyde-fixed myelodysplastic stroma was higher than on paired fixed normal stroma (11+/-10%) (n=6, p=0.056). Constitutive mean levels of superoxide in myelodysplastic cultures (9.5+/-2.1) were greater than in normal stromal cultures (4.9+/-0.6; n=6). However, following treatment with tumor necrosis factor-a, the mean value for superoxide in myelodysplastic stromal cultures was unchanged (fractional change=0.99+/-0.56), compared with an increase in normal stroma (fractional change=1.6+/-0.1, p<0.05). No correlation was observed between superoxide levels, proportion of apoptotic CD34+ cells and percentage of CD14+ stromal cells [mean 8%, range 0-37% (myelodysplastic); mean 1.3%, range 0-5% (normal)]. INTERPRETATION AND
CONCLUSIONS: Abnormalities of stromal function in myelodysplastic syndromes are likely to be heterogeneous in origin: altered matrix molecules and changes in superoxide within stromal cells may contribute to abnormal survival and development of hematopoietic cells within the myelodysplastic marrow microenvironment

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602409

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  15 in total

1.  Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients.

Authors:  Carlos Santamaría; Sandra Muntión; Beatriz Rosón; Belén Blanco; Olga López-Villar; Soraya Carrancio; Fermín M Sánchez-Guijo; María Díez-Campelo; Stela Alvarez-Fernández; María E Sarasquete; Javier de las Rivas; Marcos González; Jesús F San Miguel; María Consuelo Del Cañizo
Journal:  Haematologica       Date:  2012-02-27       Impact factor: 9.941

Review 2.  The microenvironment in myelodysplastic syndromes: Niche-mediated disease initiation and progression.

Authors:  Allison J Li; Laura M Calvi
Journal:  Exp Hematol       Date:  2017-08-18       Impact factor: 3.084

Review 3.  Oxidases and reactive oxygen species during hematopoiesis: a focus on megakaryocytes.

Authors:  Alexia Eliades; Shinobu Matsuura; Katya Ravid
Journal:  J Cell Physiol       Date:  2012-10       Impact factor: 6.384

4.  Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.

Authors:  Gergely Varga; Judit Kiss; Judit Várkonyi; Virág Vas; Péter Farkas; Katalin Pálóczi; Ferenc Uher
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

5.  Gene expression patterns in myelodyplasia underline the role of apoptosis and differentiation in disease initiation and progression.

Authors:  Merav Bar; Derek Stirewalt; Era Pogosova-Agadjanyan; Vitas Wagner; Ted Gooley; Nissa Abbasi; Ravi Bhatia; H Joachim Deeg; Jerald Radich
Journal:  Transl Oncogenomics       Date:  2008-05-29

6.  Identification of protein-coding and non-coding RNA expression profiles in CD34+ and in stromal cells in refractory anemia with ringed sideroblasts.

Authors:  Mariana O Baratti; Yuri B Moreira; Fabiola Traina; Fernando F Costa; Sergio Verjovski-Almeida; Sara T Olalla-Saad
Journal:  BMC Med Genomics       Date:  2010-07-15       Impact factor: 3.063

Review 7.  Oxidative stress and the myelodysplastic syndromes.

Authors:  Morag J Farquhar; David T Bowen
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

Review 8.  Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS).

Authors:  Peter Valent; Friedrich Wimazal; Ilse Schwarzinger; Wolfgang R Sperr; Klaus Geissler
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

9.  Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment.

Authors:  Tony Navas; Li Zhou; Myka Estes; Edwin Haghnazari; Aaron N Nguyen; Yongkai Mo; Perry Pahanish; Mani Mohindru; Tim Cao; Linda S Higgins; Leonidas C Platanias; Alan List; Amit Verma; T Bhagat; S Gajavelli; S Kambhampati
Journal:  Leuk Lymphoma       Date:  2008-10

10.  MiR-886-3p down regulates CXCL12 (SDF1) expression in human marrow stromal cells.

Authors:  Manoj M Pillai; Xiaodong Yang; Ilango Balakrishnan; Lynne Bemis; Beverly Torok-Storb
Journal:  PLoS One       Date:  2010-12-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.